New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

Just more than half of U.S. adults have gotten at least one Covid-19 vaccine dose – CDC

Just more than half of U.S. adults have received at least one Covid-19 vaccine dose, data from the U.S. Centers for Disease Control and Prevention showed on April 18, with nearly 130 million people aged 18 years or more having received their first shot.

3

Blood type not a Covid-19 risk factor in U.S.; inhaled asthma drug may keep mild illness from worsening

According to separate studies, blood type does not affect susceptibility to Covid-19 in U.S. patients and an inhaled steroid commonly used to treat asthma can help keep patients with mild Covid-19 from getting sicker.

5

Drug companies to face first opioid trial following pandemic delays

Four drugmakers, including Johnson & Johnson and Teva Pharmaceutical Industries Ltd., will go to trial on April 19 over claims they helped fuel an opioid crisis that has resulted in nearly 500,000 overdose deaths in the United States.

6

U.S. FDA Approves Opdivo in Combination with Chemotherapy for Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma

U.S. Food and Drug Administration Approves Opdivo®(nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma — Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1 April 16, 2021 […]

7

J&J Covid-19 vaccine pause to be reviewed by U.S. panel next week

A U.S. panel will meet again next week to discuss whether the pause on the use of Johnson & Johnson’s Covid-19 vaccine should continue, after delaying a vote on the matter earlier this week.

8

UK Variant Not as Lethal as Originally Reported

A new study by researchers at the University College London (UCL) published in Lancet Infectious Diseases finds that although the U.K. variant of SARS-CoV-2 known as B.1.1.7 is more transmissible than the wild-type, original Wuhan strain, it is likely not more deadly.